Company SillaJen, Inc.

Equities

A215600

KR7215600008

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Sector Bio Therapeutic Drugs

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
4,325 ^KRW	+0.35%		-9.71%	-28.28%

Apr. 22	OSR Holdings and SillaJen Enter into A Memorandum of Understanding to Collaborate the Development of Innovative Therapeutics and Enter the U.S. Market	CI
Mar. 27	SillaJen, Inc. Submits CSR to the US FDA for REN026 Study in Patients with RCC	CI

SillaJen Inc is a Korea-based company primarily engaged in the research and development of oncolytic virus immunotherapeutics. The Companyâs major product is Pexa-Vec, which is in a global Phase 3 clinical trial that is used for the treatment of liver cancer. Additionally, it also offers oncolytic virus immunotherapeutics, including SJ-102, SJ-103, SJ-815, JX-929, JX-930, JX-963, JX-970 and others.970 and others.

Number of employees: 37

KRW in Million	2022	Weight	2023	Weight	Delta
Product Supply 100.0 %	4,938	98.5 %	3,940	100.0 %	-20.22%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 100.0 %	4,938	98.5 %	3,940	100.0 %	-20.22%

Managers	Title	Age	Since
Eun-Sang Moon CEO	Chief Executive Officer	59	14-01-31
Kyung-Mi Yang CTO	Chief Tech/Sci/R&D Officer	58	-
Ji-Won Choi CTO	Chief Tech/Sci/R&D Officer	57	-
Myung-Seok Song BRD	Director/Board Member	57	-
Seong-Mi Jeong AUD	Comptroller/Controller/Auditor	59	-
Dong-Ho Kim AUD	Comptroller/Controller/Auditor	61	-
Jae-Jun Park LAW	General Counsel	48	-
Jong-Young Park AUD	Comptroller/Controller/Auditor	63	-

Members of the board	Title	Age	Since
Eun-Sang Moon CEO	Chief Executive Officer	59	14-01-31
Yong-Jae Jang BRD	Director/Board Member	57	-
Myung-Seok Song BRD	Director/Board Member	57	-
Kyung-Mi Yang CTO	Chief Tech/Sci/R&D Officer	58	-
Byung-Ju Kim BRD	Director/Board Member	55	-
Sang-Eun Joo BRD	Director/Board Member	58	-
Gwon-Hee Lee BRD	Director/Board Member	54	-
Seung-Ki Hong BRD	Director/Board Member	65	-
Byung-Wook Jeong BRD	Director/Board Member	58	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	111,125,298	80,351,488 ( 72.31 %)	81,021 ( 0.0729 %)	72.31 %

Name	Equities	%	Valuation
M2N CO.,LTD 18.23 %	18,750,000	18.23 %	71 M ₩
Eun-Sang Moon 3.588 %	3,690,637	3.588 %	14 M ₩
SILLAJEN, INC. 0.0729 %	75,000	0.0729 %	283 565 ₩
Jae-gyeong Kim 0.0194 %	20,000	0.0194 %	75 617 ₩
Korea Investment Management Co., Ltd. 0.0154 %	15,817	0.0154 %	59 802 ₩
Xact Kapitalförvaltning AB 0.009609 %	9,885	0.009609 %	37 374 ₩
Storebrand Asset Management AS 0.005769 %	5,934	0.005769 %	22 436 ₩
QS Investors LLC 0.000048 %	49	0.000048 %	185 ₩

Name	Equities	%	Valuation
SILLAJEN, INC. 0.07%	75,000	0.07%	283,565 $

SillaJen, Inc.

109, Sogong-ro

46508, Jung-gu

http://www.sillajen.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
SILLAJEN, INC.	-28.28%	325M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs